Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660065 | 0.84 | AR (0.46) | ARHPGDRXRARXRBSSTR4 | |
| SCHEMBL21387092 | 0.78 | MRGPRX4 (0.46) | MRGPRX4ARHDAC6HPGDSSTR4 | |
| SCHEMBL12571064 | 0.78 | MRGPRX4 (0.46) | MRGPRX4ARHDAC6HPGDSSTR4 | |
| SCHEMBL14433980 | 0.71 | KCNJ5 (0.45) | MRGPRX4L3MBTL1SSTR4HTT | |
| SCHEMBL6655948 | 0.71 | NPC1 (0.45) | ARHPGDMAPTSSTR4 | |
| Benzene SCHEMBL28007808 | 0.69 | CES2 (0.61) | MAOBGRIN2BL3MBTL1MAPTTDP1 | |
| SCHEMBL21748887 | 0.68 | SSTR4 (0.55) | HPGDRXRARXRBSSTR4HTT | |
| SCHEMBL21748810 | 0.68 | SSTR4 (0.53) | HPGDRXRARXRBMAPTTDP1 | |
| Water SCHEMBL27804326 | 0.67 | CES2 (0.64) | MAOB | |
| SCHEMBL5511674 | 0.67 | AR (0.46) | ARHPGDRXRARXRBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242913-A1 | Organic compounds | DUCRAY PIERRE (FR) | 2004-12-02 | — | — | US | disclosed |
| EP-1436250-A1 | CYANOACETYL COMPOUNDS | Novartis AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003031394-A1 | ORGANIC COMPOUNDS | NOVARTIG AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242913-A1 | Organic compounds | CYP1B1, BCL2A1, CYP1A1 | MRGPRX4 416/4885MAOB 190/4885AR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.